Eczema Therapeutics Market Expected to Witness Amazing Growth by 2026 with Key Players such as Cara Therapeutics, Aclaris Therapeutics, Pfizer, Incyte, Lilly, Reistone Biopharma, Leo

Research Informatic Press Release / Research Informatic released a research report on “Global Eczema Therapeutics Market”.

Market overview

The global eczema therapeutics market is expected to reach a market value of USD 6.2 billion while growing at a CAGR of 7.2% during the forecast period from 2021 to 2026. The growing awareness of eczema is expected to play an important role in driving the market over the forecast period. Moreover, increase in players’ initiatives to raise awareness about the skin condition is likely to propel the market in the coming times. For example, Pfizer, Inc. announced a new “Eczema Inside Out” program in conjunction with patient advocacy organizations in various countries. The collaboration would facilitate patient interaction with healthcare providers regarding eczema treatment. Moreover, increasing regulatory body approvals are expected to provide lucrative opportunities to the industry over the forecast period. For example, on June 25, 2021, AbbVie Inc. received approval from the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) for its drug RINVOQ (upadacitinib), a selective and reversible oral inhibitor from JAK, for expanded use in adults and adolescents with moderate to severe atopic dermatitis.

Market segmentation

The global eczema therapeutics market can be segmented into type, treatment, route of administration and region.

Based on type, the global eczema therapeutics market can be segmented into contact dermatitis and atopic dermatitis. Between the two segments, the contact dermatitis segment is expected to gain significant traction during the forecast period.

On the basis of treatment, the global eczema therapeutics market can be segmented into drugs, personal care, and biologics. The biologics market is expected to grow at the highest CAGR over the forecast period.

Based on the route of administration, the global eczema therapeutics market can be segmented into topical, oral and injectable products. The injectable segment is expected to grab a major market share over the forecast period.

On the basis of distribution channels, the global eczema therapeutics market can be segmented offline and online. Between the two, the online segment is expected to be the fastest growing segment during the forecast period.

Get a full summary of the report with 250 pages, research scope and table of contents, click here:

https://www.researchinformatic.com/reports/eczema-therapeutics-market-234

Regional analysis

According to the analysis, North America is expected to lead the market over the forecast period. The region is expected to have secured around 32% market share in 2020 and is expected to maintain its position throughout the forecast period. The CDC reveals that 10.1% of the US population has had eczema, generating an urgent need for the availability of effective treatment. In addition, the eczema treatment reimbursement plan has had a positive impact on the market. For example, US Medicare covers the treatment of eczema. Under the policy, specialist appointments, doctor visits and other special treatments are covered. APAC is expected to be the fastest growing market over the forecast period. The growth of the regional market can be attributed to the growing trend of offering advanced healthcare facilities as well as boosting lucrative opportunities for startups in countries like India and China. On the other hand, Europe is expected to register significant growth during the forecast period. The expansion can be attributed to increased research and development activities. For example, in May 2021, researchers at Trinity College Dublin conducted clinical trials for the treatment of atopic dermatitis. The researchers concluded that the drug Upadacitnib was the most effective treatment for chronic recurrent atopic dermatitis or eczema.

Key players

Prominent players in the global eczema therapeutics market include Cara Therapeutics, Aclaris Therapeutics, Pfizer, Incyte, Lilly, Reistone Biopharma, Leo and others.

The main recent developments among the major players are:

  • In November 2021, Union Therapeutics received accelerated designation from the FDA for oral orismilast for the treatment of moderate to severe atopic dermatitis.
  • In September 2021, Incyte disclosed US FDA approval of Opzelura, a monoclonal antibody to ruxolitinib cream – a JAK inhibitor for the treatment of atopic dermatitis.

COMTEX_404990415/2769/2022-03-30T09:39:41

Comments are closed.